Anastrozole (Arimidex) for Estrogen Management — Testosterone & Androgens
Non-steroidal aromatase inhibitor widely used off-label to manage estradiol levels during testosterone replacement therapy.
Overview
Anastrozole is a third-generation non-steroidal aromatase inhibitor that selectively and reversibly binds to the aromatase enzyme (CYP19A1), blocking the conversion of androgens to estrogens. Originally developed and FDA-approved for the treatment of hormone receptor-positive breast cancer in postmenopausal women, it is now one of the most commonly prescribed ancillary medications in testosterone replacement therapy (TRT) clinics. In men receiving exogenous testosterone, supraphysiologic androgen levels can lead to excessive aromatization, resulting in elevated estradiol. Symptoms of high estradiol in men include gynecomastia, water retention, mood disturbances, and sexual dysfunction. Anastrozole at low doses (0.25–1 mg every other day to twice weekly) effectively reduces estradiol by 50–70% without completely suppressing it. Complete estrogen suppression should be avoided as estradiol plays critical roles in bone mineral density, lipid metabolism, and cardiovascular health in men. The Endocrine Society guidelines note anastrozole use for symptomatic estrogen elevation during TRT, though long-term data in this population remain limited.
Indications
- FDA-approved: Adjuvant treatment of hormone receptor-positive early breast cancer in postmenopausal women
- FDA-approved: First-line treatment of advanced breast cancer in postmenopausal women
- Off-label: Estradiol management during testosterone replacement therapy
- Off-label: Gynecomastia prevention in men on TRT or anabolic steroids
- Off-label: Male infertility (increase testosterone-to-estrogen ratio)
Mechanism of Action
Anastrozole binds reversibly and competitively to the heme group of the CYP19A1 (aromatase) enzyme
Dosing
| Compound | Dose | Frequency | Notes |
|---|---|---|---|
| Anastrozole | 0.25 mg | Every other day | Starting dose for TRT estrogen management; most common clinical approach |
| Anastrozole | 0.5 mg | Twice weekly | Moderate dose for elevated E2 on standard TRT |
| Anastrozole | 1 mg | Every other day | Higher dose for refractory cases or supraphysiologic testosterone doses |
| Anastrozole | 1 mg | Once daily | FDA-approved breast cancer dosing — not typical for TRT |
Evidence Grade
GRADE B
Safety & Contraindications
- Excessive estrogen suppression can decrease bone mineral density — monitor DEXA if chronic use
- May adversely affect lipid profile (increase LDL, decrease HDL) with prolonged use
- Joint pain and arthralgias are common side effects (up to 35% in breast cancer trials)
- Hot flashes, headache, and fatigue reported
- Avoid complete estradiol suppression — maintain E2 > 15-20 pg/mL in men
- Drug interactions: potent CYP3A4 inhibitors may increase anastrozole levels